metformin hydrochloride; pioglitazone hydrochloride - Profile

What are the generic drug sources for metformin hydrochloride; pioglitazone hydrochloride and what is the scope of freedom to operate?

Metformin hydrochloride; pioglitazone hydrochloride is the generic ingredient in three branded drugs marketed by Takeda Pharms Usa, Aurobindo Pharma Ltd, Chartwell Rx, Macleods Pharms Ltd, Pharmobedient, Teva Pharms Usa, and Torrent Pharms Ltd, and is included in eight NDAs. There are four patents protecting this compound and two Paragraph IV challenges. Additional information is available in the individual branded drug profile pages.

Metformin hydrochloride; pioglitazone hydrochloride has one hundred and thirteen patent family members in thirty-two countries.

Summary for metformin hydrochloride; pioglitazone hydrochloride

International Patents:	113
US Patents:	4
Tradenames:	3
Applicants:	7
NDAs:	8
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for metformin hydrochloride; pioglitazone hydrochloride

Paragraph IV (Patent) Challenges for METFORMIN HYDROCHLORIDE; PIOGLITAZONE HYDROCHLORIDE

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
ACTOPLUS MET XR	Extended-release Tablets	metformin hydrochloride; pioglitazone hydrochloride	15 mg/1000 mg and 30 mg/1000 mg	022024	1	2011-09-23

US Patents and Regulatory Information for metformin hydrochloride; pioglitazone hydrochloride

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Takeda Pharms Usa	ACTOPLUS MET XR	metformin hydrochloride; pioglitazone hydrochloride	TABLET, EXTENDED RELEASE;ORAL	022024-001	May 12, 2009		DISCN	Yes	No			Y
Takeda Pharms Usa	ACTOPLUS MET XR	metformin hydrochloride; pioglitazone hydrochloride	TABLET, EXTENDED RELEASE;ORAL	022024-001	May 12, 2009		DISCN	Yes	No			Y
Takeda Pharms Usa	ACTOPLUS MET XR	metformin hydrochloride; pioglitazone hydrochloride	TABLET, EXTENDED RELEASE;ORAL	022024-002	May 12, 2009		DISCN	Yes	No			Y
Takeda Pharms Usa	ACTOPLUS MET XR	metformin hydrochloride; pioglitazone hydrochloride	TABLET, EXTENDED RELEASE;ORAL	022024-002	May 12, 2009		DISCN	Yes	No			Y
Takeda Pharms Usa	ACTOPLUS MET	metformin hydrochloride; pioglitazone hydrochloride	TABLET;ORAL	021842-001	Aug 29, 2005		DISCN	Yes	No			Y
Takeda Pharms Usa	ACTOPLUS MET	metformin hydrochloride; pioglitazone hydrochloride	TABLET;ORAL	021842-001	Aug 29, 2005		DISCN	Yes	No			Y
Takeda Pharms Usa	ACTOPLUS MET	metformin hydrochloride; pioglitazone hydrochloride	TABLET;ORAL	021842-002	Aug 29, 2005	AB	RX	Yes	Yes			Y

Expired US Patents for metformin hydrochloride; pioglitazone hydrochloride

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Takeda Pharms Usa	ACTOPLUS MET XR	metformin hydrochloride; pioglitazone hydrochloride	TABLET, EXTENDED RELEASE;ORAL	022024-001	May 12, 2009
Takeda Pharms Usa	ACTOPLUS MET	metformin hydrochloride; pioglitazone hydrochloride	TABLET;ORAL	021842-001	Aug 29, 2005
Takeda Pharms Usa	ACTOPLUS MET XR	metformin hydrochloride; pioglitazone hydrochloride	TABLET, EXTENDED RELEASE;ORAL	022024-002	May 12, 2009
Takeda Pharms Usa	ACTOPLUS MET	metformin hydrochloride; pioglitazone hydrochloride	TABLET;ORAL	021842-001	Aug 29, 2005
Takeda Pharms Usa	ACTOPLUS MET XR	metformin hydrochloride; pioglitazone hydrochloride	TABLET, EXTENDED RELEASE;ORAL	022024-001	May 12, 2009
Takeda Pharms Usa	ACTOPLUS MET XR	metformin hydrochloride; pioglitazone hydrochloride	TABLET, EXTENDED RELEASE;ORAL	022024-001	May 12, 2009
Takeda Pharms Usa	ACTOPLUS MET XR	metformin hydrochloride; pioglitazone hydrochloride	TABLET, EXTENDED RELEASE;ORAL	022024-001	May 12, 2009

International Patents for metformin hydrochloride; pioglitazone hydrochloride

Country	Patent Number	Title	Estimated Expiration
China	1717253	Solid preparation
Japan	4694841
Australia	2006232993	Novel pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative
Japan	2006502187
Spain	2541124
South Korea	101249171
New Zealand	580804	Novel pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative

Supplementary Protection Certificates for metformin hydrochloride; pioglitazone hydrochloride

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
1412357	SPC/GB08/040	United Kingdom		PRODUCT NAME: SITAGLIPTIN OPTIONALLY IN THE FORM OF A PHARMACEUTICALLY ACCEPTABLE SALT, IN PARTICULAR THE MONOPHOSPHATE, PLUS METFORMIN OPTIONALLY IN THE FORM OF A PHARMACEUTICALLY ACCEPTABLE SALT, IN PARTICULAR THE HYDROCHLORIDE.; REGISTERED: CH 58450 01-03 20080408; UK EU/1/08/455/001 20080716; UK EU/1/08/455/002 20080716; UK EU/1/08/455/003 20080716; UK EU/1/08/455/004 20080716; UK EU/1/08/455/005 20080716; UK EU/1/08/455/006 20080716; UK EU/1/08/455/007 20080716; UK EU/1/08/455/008 20080716; UK EU/1/08/455/009 20080716; UK EU/1/08/455/010 20080716; UK EU/1/08/455/011 20080716; UK EU/1/08/455/012 20080716; UK EU/1/08/455/013 20080716; UK EU/1/08/455/014 20080716
2498758	122020000018	Germany		PRODUCT NAME: METFORMIN ODER EIN PHARMAZEUTISCH AKZEPTABLES SALZ DAVON; SAXAGLIPTIN ODER EIN PHARMAZEUTISCH AKZEPTABLES SALZ DAVON; DAPAGLIFLOZIN ODER EIN PHARMAZEUTISCH AKZEPTABLES SOLVAT DAVON; REGISTRATION NO/DATE: EU/1/19/1401 20191111
2498758	301040	Netherlands		PRODUCT NAME: METFORMINE OF EEN FARMACEUTISCH AANVAARDBAAR ZOUT DAARVAN; SAXAGLIPTINE OF EEN FARMACEUTISCH AANVAARDBAAR ZOUT DAARVAN; DAPAGLIFLOZINE OF EEN FARMACEUTISCH AANVAARDBAAR SOLVAAT DAARVAN; REGISTRATION NO/DATE: EU/1/19/1401 20191113
1412357	C 2008 016	Romania		PRODUCT NAME: SITAGLIPTIN OPTIONAL SUB FORMA DE SARE ACCEPTABILAFARMACEUTIC IN SPECIAL MONOFOSFAT + METFORMIN OPTIONAL SUB FORMA DE SARE ACCEPTABILA FARMACEUTIC IN SPECIALCLORHIDRAT; NATIONAL AUTHORISATION NUMBER: RO EU/1/08/455/001 - RO EU/1/08/455/014; DATE OF NATIONAL AUTHORISATION: 20080716; NUMBER OF FIRST AUTHORISATION IN EUROPEAN ECONOMIC AREA (EEA): CH 58450 01, CH 58450 02, CH 58450 03; DATE OF FIRST AUTHORISATION IN EEA: 20080408
1506211	179 5017-2014	Slovakia		PRODUCT NAME: KOMBINACIA DAPAGLIFLOZINU ALEBO JEHO FARMACEUTICKY PRIJATELNYCH SOLI A METFORMINU ALEBO JEHO FARMACEUTICKY PRIJATELNYCH SOLI; REGISTRATION NO/DATE: EU/1/13/900/001 - EU/1/13/900/012 20140116
1412357	132008901682802	Italy		PRODUCT NAME: SITAGLIPTIN/METFORMINA CLORIDRATO(JANUMET, VELMETIA, EFFICIB); AUTHORISATION NUMBER(S) AND DATE(S): JANUMET:EU/1/08/455/001... 014; VELMETIA:EU/1/08/456/001...014;EFFICIB: EU/1/08/457/001....014, 20080716;58450-01;58450-02; 58450-03, 20080408
1261586	C01261586/02	Switzerland		PRODUCT NAME: SAXAGLIPTIN UND METFORMIN; NAT. REGISTRATION NO/DATE: SWISSMEDIC 62040 20120329

Investment Scenario, Market Dynamics, and Financial Trajectory for Metformin Hydrochloride and Pioglitazone Hydrochloride

Last updated: February 3, 2026

Executive Summary

This report analyzes the current investment landscape, market dynamics, and projected financial performance for two foundational antidiabetic drugs: metformin hydrochloride and pioglitazone hydrochloride. Both drugs occupy significant positions in Type 2 Diabetes Mellitus (T2DM) management, with a combined market that is likely to experience steady growth driven by expanding diabetes prevalence, patent challenges, and evolving therapeutic guidelines. We provide a comprehensive overview of market size, competitive positioning, regulatory trends, and future revenue forecasts.

---

1. Market Overview and Investment Outlook

Parameter	Details
Global T2DM Market Size (2022)	Approx. USD 80 billion (statista.com)
Annual Growth Rate (CAGR, 2023-2028)	5-7% (Grand View Research)
Key Players (market share, 2022)	Novo Nordisk, Eli Lilly, Mylan, Teva, Sun Pharma
Leading Drugs	Metformin (~70% market share of oral antidiabetics), Pioglitazone (~10-15%)
Patent Status	Metformin: off-patent; Pioglitazone: patent expired/lost exclusivity

Investment Perspective:
The combination of widespread use, established safety profiles, and patent expiries positions generics manufacturers favorably. Yet, innovation is limited, with growth dependent on market expansion, biosimilars, and combination therapies.

---

2. Market Dynamics of Metformin Hydrochloride

2.1 Market Size and Growth Drivers

Parameter	Figures & Notes
Global Market Size (2022)	USD 35 billion (approximate)
Projected CAGR (2023-2028)	6-7%
Usage Share	First-line therapy (~80% of T2DM patients)
Main Drivers	Rising diabetes prevalence, generic availability, low cost

Notes:
Metformin remains the cornerstone of T2DM management in both developed and emerging markets, with robust demand from healthcare systems emphasizing cost-effective treatment.

2.2 Market Segmentation

Segment	Details	Market Share (2022)
Branded	Limited, mostly in emerging markets	20%
Generic	Dominates due to patent expiry	80%

2.3 Competitive Landscape

Key Manufacturers	Market Share (Estimated)	Notes
Mylan, Teva, Sun Pharma	30-40% combined	Leading generics players
Local pharmaceutical companies	Remaining share	Significant in emerging markets

2.4 Regulatory & Pricing Trends

• Pricing Pressure: Increased with generic proliferation.
• Regulatory Concerns: Concerns over manufacturing quality and bioequivalence standards.
• Market Access: Growing adoption facilitated by price sensitivity in low- and middle-income countries.

---

3. Market Dynamics of Pioglitazone Hydrochloride

3.1 Market Size and Growth Drivers

Parameter	Figures & Notes
Global Market Size (2022)	USD 2.5 billion (approximate)
Projected CAGR (2023-2028)	4-6%
Use Cases	As monotherapy or combination therapy
Main Drivers	Rising insulin resistance, off-label use, patents expired

Notes:
Pioglitazone’s market has been constrained by safety concerns (notably cardiovascular and bladder cancer risks) leading to cautious prescribing, especially in the US and Europe.

3.2 Market Segmentation

Segment	Details	Market Share (2022)
Brand Name Sales	Actos (Takeda), generic versions as well	Limited due to regulatory concerns
Generic	Growing in emerging markets	Approx. 70%

3.3 Competitive Landscape

Key Manufacturers	Market Share (Estimated)	Notes
Various generics manufacturers	80-85%	Due to patent expiry
Takeda Pharmaceuticals (Actos)	Declining	Withdrawn from some markets due to safety risks

3.4 Regulatory & Safety Considerations

• FDA Status: Restricted, with warnings for long-term use.
• European Medicines Agency (EMA): Observed, with restrictions in some countries.
• Market Impact: Reduced prescribing, but usage persists in some regions for select patient populations.

---

4. Future Financial Trajectory and Investment Opportunities

Parameter	Metformin	Pioglitazone
Revenue (2022)	USD 30-35 billion	USD 2-3 billion
Estimated 2028 Revenue	USD 45-50 billion	USD 3-4 billion
Growth Drivers	Rising diabetes prevalence, generics, biosimilars	Increased use in combination therapies, biosimilars, and new formulations

Forecast Summary (2023-2028)	Metformin	Pioglitazone
Compound Annual Growth Rate (CAGR)	6-7%	4-6%
Key Investment Risks	Market saturation, safety concerns, regulatory shifts	Evolving safety perception, regulatory restrictions

---

5. Regulatory and Policy Considerations

Region	Regulations & Policies	Impact on Market
United States	FDA warnings, off-label restrictions	Reduced use of pioglitazone; stable demand for metformin
European Union	EMA warnings, increased monitoring	Market shift towards newer agents
Emerging Markets	Less stringent regulation, higher generic penetration	Growing demand, high investment potential

6. Comparative Analysis: Key Differentiators

Criterion	Metformin Hydrochloride	Pioglitazone Hydrochloride
Patent Status	Off-patent	Patent expired/lost exclusivity
Market Dominance	First-line, widespread use	Niche, cautious use
Safety Profile	Generally well-tolerated	Safety concerns have limited use
Cost	Very low, highly competitive	Moderate, depending on formulation

---

7. Investment Risks and Challenges

Risk Factor	Description	Mitigation Strategy
Regulatory changes	Stricter safety warnings impacting use	Diversify portfolio with newer agents
Market saturation	Excess supply in mature markets	Focus on emerging markets and biosimilars
Safety concerns (Pioglitazone)	Limited future growth	Emphasize combination therapies with newer drugs
Pricing pressures	Ongoing commoditization	Innovate in formulations or biosimilars

---

8. Strategic Recommendations

• For Manufacturers: Focus on biosimilars, combination formulations, and expanding in emerging markets, where penetration remains low.

• For Investors: Prioritize companies with a diversified portfolio in antidiabetics, especially those investing in novel formulations or biosimilar pipelines.

• For Pharma Developers: Invest in research targeting improved safety profiles or novel mechanisms for existing classes.

---

Key Takeaways

• Metformin hydrochloride remains the most significant and stable revenue generator within antidiabetics, benefiting from off-patent status, low-cost manufacturing, and widespread adoption.
• The market for pioglitazone is diminishing in developed countries due to safety issues, yet it retains relevance in emerging markets and as part of combination therapies.
• Growth prospects for both drugs hinge on expanding access in emerging markets, biosimilar competition, and integration into combination therapies.
• Regulatory shifts influence market trajectories, especially safety warnings that can limit prescribing and impact revenue.
• Investment opportunities are most promising among generic manufacturers, biosimilar developers, and companies with diversified diabetic portfolios.

---

FAQs

Q1: What is the projected market growth for metformin hydrochloride over the next five years?
A: The global metformin market is expected to grow at a CAGR of approximately 6-7% from 2023 to 2028, driven by increasing prevalence of T2DM and expanding access in developing regions.

Q2: How do safety concerns impact pioglitazone’s market?
A: Safety issues, including risks of cardiovascular events and bladder cancer, have led regulatory restrictions and decreased prescribing, limiting the drug's market in developed countries but maintaining niche use in emerging markets.

Q3: What are the key regulatory trends affecting these drugs?
A: Regulatory agencies worldwide are imposing warnings and restrictions based on safety data. While metformin remains largely unaffected, pioglitazone faces restrictions that influence its market size.

Q4: Which regions offer the most growth potential?
A: Emerging markets in Asia, Africa, and Latin America present significant growth opportunities due to rising diabetes prevalence and less saturated markets.

Q5: What are the main opportunities for generics manufacturers?
A: High demand for cost-effective therapies, patent expiries, and increasing access in developing economies provide lucrative opportunities, especially through biosimilars and combination drugs.

---

References

1. Statista. (2022). Global Diabetes Market Size.
2. Grand View Research. (2022). Antidiabetic Drugs Market Analysis.
3. Mylan and Teva Annual Reports (2022).
4. FDA and EMA safety communications (2022).
5. World Health Organization. (2021). Diabetes Data and Statistics.

---